Reporting & SEC Filings

KEY CHARACTERISTICS • Excellent chemical resistance • Low moisture uptake • Comparable dimensional stability to nylon • Reinforced with 10–33% glass fill • High impact and wear resistance • Eco-conscious alternative to PA66 and PA6 MARKETS & APPLICATIONS Whether using a standard or customized formulation, the PK-based Trilliant grades provide a high-performing, cost-competitive, and more eco-conscious alternative to competitive materials found in biopharmaceutical processing, hospital settings, and home healthcare applications. STANDARD COLORS FOR BIOPHARMACEUTICAL APPLICATIONS GLASS FILL COLOR PRODUCT NAME Bright White HC8910-0004 RS 20% HC8910-0017 RS 33% HC8910-0018 RS Cool Gray 1C HC8910-0005 RS 20% HC8910-0006 RS Cool Gray 3C HC8910-0007 RS 20% HC8910-0008 RS Warm Gray 1 C HC8910-0009 RS 20% HC8910-0010 RS TPX 12-0703 Tan HC8910-0011 RS 20% HC8910-0012 RS 542C Blue HC8910-0013 RS 20% HC8910-0014 RS 301C Blue HC8910-0015 RS 20% HC8910-0016 RS Colors may vary from actual color shown

ATTRIBUTE PC PUMP PERI PUMP CMG3000 FLEX G CMG5000 CMG6000 Delivery throughput High Low – – – – Metering throughput High Low – – – – Volumetric/gravimetric V V V Loss-in-weight G G Data export/network – – No Yes Yes Yes Touch screen – – No Yes Yes Yes Multiple log-in levels – – No No Yes Yes The range of progressing cavity pump rates attainable can be used to determine the correct size of pump.

ATTRIBUTE PC PUMP PERI PUMP CMG 3000 CMG 5000 Metering throughput High Low – – Volumetric/gravimetric V V V V/G Data export/network – – No Yes Touch screen – – No Yes Multiple log-in levels – – No Yes The range of progressing cavity pump rates attainable can be usedto determine the correct size of pump.

Reporting & SEC Filings

SEC Filings

name change effective from 17/05/2021) :Company Name 201916958NUEN : This is to confirm that the company was incorporated under the Companies Act, on and from 27/05/2019 and that the company is a PRIVATE COMPANY LIMITED BY SHARES. The company was formerly known as: S/N Company Name Effective From 1. LTD. 27/05/2019 (Note: Only the five (5) most recent former names are listed.

• The Committee will consist entirely of directors who the Board has determined have no material relationships with the Company, either directly or as a partner, shareholder, or officer of an organization that has a relationship with the Company, and: o who meet the definition of “independent” as set forth in the Corporate Governance Standards of the New York Stock Exchange; and o qualify as “non-employee directors” for the purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). • Each Committee member will serve at the pleasure of the Board for such term as the Board may decide or until such Committee member is no longer a Board member. With the assistance of management and any outside advisers the Committee deems appropriate (a) review and discuss with management the Company’s disclosures in the CD&A, and, based on this review, make a recommendation as to whether to include it in the Company’s annual report on Form 10-K and proxy statement relating to the Company’s annual meeting of shareholders, and (b) prepare a Compensation Committee Report for inclusion in the Company’s proxy statement or other applicable SEC filings. 4 Board Reports and Annual Evaluation Committee Meetings and Action • A majority of the Committee members will be a quorum for the transaction of business. • The action of a majority of those present at a meeting at which a quorum is present will be the act of the Committee. • Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary

Documented change control beyond CAS number is practiced and Registered Drug Master File (DMF) / Device Master File (MAF) documentation is maintained. 

Documented change control beyond CAS number and Registered Drug Master File (DMF)/Device Master File (MAF) documentation are common practices for the Mevopur portfolio.